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INTRODUCTION
Established non-insulin dependent diabetesmellitus
(NIDDM) is associatedwith profound insulin secretary
defects, which occur along with insulin resistance.
These two fundamental defects, which are major
factors in the pathogenesis of NIDDM, are caused by
a combination of genetic and environmental factors
(1). Little is known of the molecular basis for these
abnormalities and it is difficult to study them in
human subjects. Animal models, however, do provide
an opportunity to study this problem. The develop-
ment of diabetes in the Wistar fatty male rat, which
has been established by transferring the fa gene of
the Zucker fatty rat to the Wistar Kyoto rat (2), has
many features in common with human NIDDM, in
that the animals exhibit hyperglycemic obesity with
hyperinsulinemia and insulin resistance. Ikeda et
al . (2) have reported insulin resistance as a cause
for diabetes mellitus in this model rat. Recently, we
reported a failure of pancreatic β-cell proliferation
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as a cause of sustained hyperglycemia, induced by
a 70% pancreactectomy in a model of spontaneous
NIDDM, the Otsuka Long-Evans Tokushima Fatty
(OLETF) rat (3, 4). This may represent a funda-
mental etiological factor in the onset of overt diabetes.
Impaired β-cell proliferation has been also reported
to be etiologically related to the development ofNIDDM
in the other NIDDMmodel animals (5, 6). To determine
whether β-cell proliferation is impaired, whether the
subsequent reduction of β-cell mass is also related
to NIDDM in the Wistar Fatty model, and whether
any differences in the capacity for proliferation of β-cell
betweenWistar lean ratswith ahomogeneousgenotype
(Fa/Fa) and a hetero-geneous genotype (Fa/fa) exist,
we used partially pancreatectomized rats as a model
as was previously done for the case of OLETF rats.
For this purpose, the compensatory capacity of the
pancreatic remnant was determined by comparing
alterations in blood glucose levels and compensatory
proliferation of the remnant pancreas in Wistar fatty
and non-fatty litter mates, Wistar lean with Fa/Fa and
Fa/fa. In addition, we examinedwhether diabetes was
caused by partial pancreatectomy in thesemodel rats,
and if so, whether it could be prevented by the
adminstration of nicotinamide.
RESERCH DESIGN AND METHODS
Animals
The Wistar fatty rat, which was established by
transferring the fa gene of Zucker fatty rat to the
Wistar Kyoto rat, genetically develops both obesity
and diabetes. According to Ikeda et al . (2), plasma
glucose reaches a hyperglycemic level in excess of
16.7 mmol/l at as early as 8 weeks of age in male
Wistar fatty rats, but this does not occur in their lean
litter mates. Male Wistar fatty and lean rats, 4weeks
of age, were obtained from the Takeda Pharmaceutical
Co., and weremaintained in our animal facilities under
specific pathogen-free conditions (Institute of Animal
Experimentation, Tokushima University). The tem-
perature (21±2℃), humidity (55±5%), lighting
(07:00-19:00), and air conditioning were all controlled.
The animals were supplied with a standard rat diet
(Oriental Yeast, Tokyo, Japan) and tap water ad libitum.
Experimental design
Experiments were performed on rats of 6 weeks
of age at the beginning of the study. The rats were
allocated at random into two groups : partial pancre-
atectomy (Px) and sham-pancreatectomy (sham).
The animals from the Px group were treated with
either phlorizin, nicotinamide or normal saline. A total
of 5-7 rats were used for each condition for each
strain.
Genotyping
In order to determine the genotype of Wistar rats,
we followed the method developed by Phillips et al.
(7). Genomic DNA was extracted from the tail by
proteinase K digestion followed by phenol/chloroform
extraction and ethanol precipitation (8). Primers
5’-GTT TGC GTA TGG AAG TCA CAG-3’and 5’-
ACC AGC AGA GAT GTA TCC GAG-3’were used
to amplify the OB-R gene from 5ng of genomic DNA.
The PCR conditions were 94℃ for 30s, 60℃ for 30s
and 72℃ for1min. The PCR products were digested
with Hap II and analyzed on an agarose gel (9).
70% pancreatectomy (Px)
After an overnight fast, animals were anesthetized
with ether and given additional ether, if reguired
during surgery. All pancreatic tissue was removed
by gentle abrasion with a cotton applicator, expect
for an anatomically well-defined remnant, which is
bordered by a branch of the hepatic portal vein and
the first portion of the duodenal loop. The sham
operation was performed by disengaging the pan-
creas from the mesentery and gently rubbing it between
the fingers. After surgery, the rats were given access
to food and water ad libitum.
In the first week after surgery, body weight and
non-fasting plasma glucose concentrations weremea-
sured daily at 4 : 00-5 : 00 P.M. and thereafter once
a week at the same time of day. Blood samples were
obtained by tail snipping. Phlorizin (400mg/kg body
wt. per day), prepared as a 20% solution in propyl-
ene glycol, was administrered subcutaneously and
divided into three equal doses at 8-h intervals to ensure
continuous day-long inhibition of renal tubular glucose
reabsorption inWistar fatty rats alone. Nicotinamide
(350mg/kg body wt.) and normal saline were injected
intraperitoneally once a day. The injections were
initiated 2 days after surgery and were continued
until 28 days after surgery. The last injection was
given 15 h before sacrifice.
Body composition
The lean body masswasmeasuredwith an EM-SCAM
model ISA-2 (EM-SACAN, IL). The total fat volume
was calculated from the body weight and the value
for the lean body mass.
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Tissue processing
At 4 weeks after treatment (10 weeks of age),
animals were fasted overnight and then sacrificed
under deep anesthesia. The abdomen was quickly
opened, and the pancreas or remnant pancreas was
excised, cleared of extraneous lymph nodes and fat,
weighed, and divided into two lengthwise portions
to avoid bias due to regional variation in islet dis-
tribution and cell composition. One of the portions
was cassetted in the same anatomic orientation ; placed
in Bouin’s fixation ; and processed for paraffin em-
bedding using a standard protocol. The other portion
was frozen in liquid nitrogen and stored at -80℃.
On a single day, all samples of pancreas or Px remnant
stored at -80℃were individually homogenized using
a polytron homogenizer (Kinematica, Switzerland)
with 20ml cold acidified-ethanol per gram of tissue,
kept at 4℃ overnight, and centrifuged at 600 g for
30min, and the supernatant was then stored at -80℃
until assay for insulin immunoreactivity (IRI).
Assays
Non-fasting plasma glucose values were determined
by the glucose oxidasemethod (Toecho Super, Kyoto
Daiichi Kagaku, Kyoto, Japan). The measurement
of plasma IRI and IRI in tissue extracts was deter-
mined using a commerically available IRI kit (Eiken
Kagaku Co., Tokyo, Japan) with rat insulin (Novo,
Bagsvared, Denmark) as a standard.
Quantitative morphometrics
Two sets of three serial sections (3-5μm thick)
were obtained at intervals of about 300μm. The sections
were first deparaffined, and then immunostained
using an ABC kit (Amersham, UK) for insulin im-
munostaining. The primary antibody used was poly-
clonal guinea pig anti-porcine insulin antibody (1 :
400, Dako Carpinteria, USA). Using Weibel’s point
counting morphometrics (10), the relative volume
(%) of β-cell mass was quantitated at a 200 x mag-
nification using a 96-point grid with a minimum of
9600 points in 100 fields. Starting at a random point
in one corner of the section, β-cell mass was scored
in every other field. The relative volume (%) of β-cell
mass was taken as the number of intercepts over that
specific tissue as a proportion of the total counts over
pancreatic tissues. To obtain an absolute β-cell mass
(mg), the relative volume (%) of β-cell mass for each
pancreas was multipied by its tissue weight. All ob-
servations were made by one person (T.O.).
Statistics
All data are expressed as means±S.E. The insulin
content was calculated for each rat as the product
of insulin concentration and tissue weight. The sta-
tistical significance of difference was evaluated using
one-way analysis of variance (ANOVA). Differences
were considered statistically significant at P<0.05.
RESULT
Abdominal fat and fasting IRI
Abdominal fat deposits, which consist of mesenteric,
retroperitoneal and epididymal fat in the shamWistar
fatty rats, were about three times those in shamWistar
lean rats (Table 1). In addition, fasting plasma IRI
levels in the sham Wistar fatty rats were about 10
times those in the sham Wistar lean rats. However
in the case of partial pancreatectomy, the fasting plasma
IRI levels in the PxWistar fatty rats were only double
those in the PxWistar lean rats, suggesting that insulin
secretion in the Px Wistar fatty rats failed to meet
the demand.
Non-fasting blood glucose concentrations and Body
weights
Figure 1 shows the effects of 70% pancreatectomy
on non-fasting plasma glucose concentrations andbody
weight in the various groups during the experiment.
In the Px Wistar fatty rats, a marked hyperglycemia
(>20mmol/l) was detected the first day after surgery,
which was maintained for the remainder of the ex-
periment. The rate of body weight increase in the Px
Wistar fatty rats was significantly slower than that
in the sham Wistar fatty rats. In addition, in the Px
Wistar lean rats, neither hyperglycemia nor smaller
increment in body weight compared with the sham
Wistar lean rats was noted after surgery. In the Px
Wistar fatty rats, non-fasting plasma glucose values
sharply declined after phlorizin injection and subse-
quently remained at levels comparable to the sham
rats. However, non-fasting plasma glucose values in
the nicotinamide treated PxWistar fatty rats decreased
gradually and remained at a level that was signifi-
cantly higher than that of the sham rats but lower
than that of the saline-treated Px rats (Fig. 2A). The
body weight of the Px group was significantly lower
than that of sham group (Fig. 2B).
Insulin content and pancreatic β-cell mass
Table 2. shows the insulin content and pancreatic
β-cell mass in the Px remnant pancreas, remnant
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equivalent, and whole pancreas of the sham-operated
rats. In addition, insulin content and β-cell mass in
the remnant pancreas of the Px rats and the remnant
equivalent pancreas of the sham-operated rats as a
percentage of those in whole pancreas are shown
in Fig. 3. Both insulin content and β-cell mass of the
Px Wistar fatty rats treated with saline were signif-
icantly less than 30% of the whole pancreas. The same
was true for the Px Wistar fatty rats, which had been
treated with phlorizin or nicotinamide, although the
β-cell mass tended to be higher in the latter groups.
In the Px Wistar lean rats, the β-cell mass volume
was maintained at the same level as that of the
sham-operated rats, but the insulin content in the
remnant pancreas was considerably higher than the
expected value of 30%. As shown in Table 2, the insulin
content per unit β-cell mass in the remnant pancreas
of the Px Wistar lean rats treated with either saline
or nicotinamide was significantly greater than that
in the remnant equivalent pancreas of the sham rats,
while that of Px Wistar fatty rats treated with saline
or nicotinamide was decreased, compared to their
sham-operated counterparts. Although the number of
animals was too small to properly evaluate the data
statistically, no discernible differences in the various
parameters shown in Table 3 between the Wistar lean
rats with Fa/Fa and those with Fa/fa, were observed.
＃＃
** ** **
Table 1. Effect of phlorizin and nicotinamide on fasting plasma glucose and IRI levels, and anthropometric parameters in Px
Wistar fatty and lean rats.
Fasting plasma
Rat Glucose
(mmol/l)
IRI
(pmol/l)
LBM
(g)
Abdominal fat
(g)
Fat
(%)
Fatty
Lean
Px
Saline (5)
Nicotinamide (6)
Phlorizin (7)
Sham (6)
Px
Saline (6)
Nicotinamide (6)
Sham (6)
13.2±1.04
11.05±1.30
7.06±0.59
10.38±2.33
6.69±0.32
5.93±0.32
5.75±0.36
451.53±55.57
624.63±82.92
356.62±37.93
3480.11±955.39
200.24±30.23
323.55±17.71
338.08±57.37
208.16±7.05
217.10±7.04
212.63±7.05
252.01±4.44
249.62±3.70
239.38±9.84
265.19±3.56
15.03±0.71
15.83±1.06
15.43±1.05
24.09±1.03
6.74±0.38
6.24±0.47
8.49±0.64
13.49±1.44
13.71±1.39
13.60±1.42
27.92±1.07
7.01±1.20
6.83±1.08
7.21±0.95
Date are means±S.E. The samples were taken at the end of the experiment, 28 days after sugery.
LBM : Lean body mass.
Nicotinamide : Nicotinamide (350mg/kg body weight) was injected intraperitoneally daily from2days after surgery until 28 days after surgery.
Phlorizin : Phlorizin (400 mg/kg body weight per day) was injected subcutaneously three times per day in the same manner as that
of nicotinamide.
**p<0.01 vs. all other Wistar fatty groups, and ##P<0.01 vs. phlorizin-treated Px Wistar fatty group.
Fig.1. Effects of 70% pancreatectomy on non-fasting plasma
glucose levels (A) and body weights (B) of Px Wistar fatty (●-
●), sham Wistar fatty (○-○), Px Wistar lean (■-■), and sham
Wistar lean (□□) rats during the period of observation. Points
and bars are expressed as means±S.E. **p<0.01 vs. all other
groups in A. †p<0.05 and ††p<0.01 vs. shamWistar fatty in B.
**
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DISCUSSION
The 70% pancreatectomy caused a sustained
hyperglycemia in the Wistar fatty rats, but it did not
result in the elevation of non-fasting plasma glucose
levels in the Wistar lean rats. These findings, which
are similar to those of spontaneous NIDDM rats,
OLETF as reported previously (4), suggest that the
remnant pancreas cannot meet insulin demand in
the Wistar fatty rats but does so in the Wistar lean
rats, despite the similar remaining pancreatic mass
just after surgery. According to Ikeda et al. (2), in a
glucose tolerance test at 8 weeks of age, Wistar fatty
rats showed a comparable value to Wistar lean rats
for the incremental glucose area but a higher
value for the incremental insulin area.This suggests that
the former rats were less sensitive to insulin, and,
as a result, requiredmore insulin tomeet the demand.
It is quite possible to presume that the β-cell mass
in the remnant pancreas in the Wistar fatty rats is
not sufficiently large to meet this increased demand
for insulin, resulting in a relative insulin insufficiency
and, hence, a sustained hyperglycemia. Consistent
with this hypothesis, our results show that both β-
cell mass and insulin content are significantly decreased
in the remnant pancreas of the Px Wistar fatty rats
compared with those in the remnant equivalent of
the sham rats after surgery, resulting in an insufficient
increase in plasma insulin level in the PxWistar fatty
rats in the face of an increased demand for insulin
due to insulin insensitivity.
There was, however, no significant decrease in β-cell
mass and insulin content in the Px Wistar lean rats
after surgery. The remaining β-cell mass and insulin
content in the remnant pancreas might be sufficiently
large to meet the demand for less insulin and main-
tain the normal plasma glucose level because of less
resistance to insulin in these rats, compared to the
Fig.2. Effect of phlorizin (400mg/kg wt per day) and nicotinamide
(350mg/kg wt per day) on non-fasting plasma glucose levels (A)
and body weight (B) in phlorizin-treated (▲-▲), nicotinamide-
treated (■-■), and saline-treated (●-●) Px and sham (○-○)
rats after 70% pancreatectomy. Injections were begun 2 days
after surgery and continued at daily intervals until 28 days after
surgery. The findings for control Wistar lean rats after surgery
and injections were the same as those sham in Fig.1. (data not
shown). **p<0.01 and p<0.01 vs. saline treated rats in A, and
##p<0.01 vs. all other groups in B.
Fig.3. Insulin content and β-cell mass in remnant pancreas of
phlorizin ( ), nicotinamide ( ), saline-treated (■), PxWistar
rats and remnant equivalent of the counterpart sham rats (□)
28days after surgery. Values are mean±S.E. *p<0.05, **p<0.01
Vs. sham Wistar fatty.
The Journal of Medical Investigation Vol.45 1998 １０７
fatty counterparts. However, contrary to the control
Px LETO rats, which demonstrated a compensatory
increase in β-cell mass after surgery, the Px Wistar
lean rats maintained β-cell mass at the same level as
that of the sham rats. An important issue, then, is why
the β-cell mass in the Px of Wistar lean rats was not
increased after surgery as it was in the Px LETO rats.
It is possible that the pancreatic β-cell per se may
have some genetic defects in proliferative capacity in
the Wistar rat strain. This possibility is supported by
Ikeda's finding (2) that Zucker fatty rats show euglycemia
with a compensatory hyperinsulinemiawhile theWistar
fatty rats demonstrate hyperglycemia, which is ac-
companied by a lower plasma insulin level relative
to that in the Zucker fatty rats. The β-cells of the Wistar
strain might be incapable of increasing their mass
in order to meet an increased demand for insulin in
the presence of insulin resistance. Because of insulin
insensitivity due to extreme obesity, the islets are
forced to secrete more insulin to overcome the loss
of normal insulin sensitivity, which may put a stress
on pancreatic β-cells, leading to their damage and death
resulting in a reduction inβ-cell mass and insulin con-
tent. This might also be the case in Px Wistar fatty
rats.
We also found that this insufficient compensatory
capacity for β-cell growth was unaffected by the
presence or absence of hyperglycemic stimulation
in the Px Wistar rats at 28 days after surgery, as
evidenced by the administration of phlorizin. It has
**
**
**
**
**
**
**
**
**＃＃
**
**
**
Table 2. Effect of phlorizin (400mg/kg wt per day) and nicotinamide (350mg/kg wt per day) on insulin contents and β-cell mass
in remnant pancreas of 70% Px rats and in remnant equivalent and whole pancreas of sham-pancreatectomized rats.
Insulin β-cells Insulin content
per unit β-cell mass
(μg/mg)
Rat Content
(μg)
Concentration
(μg/g)
β-cell mass
(mg)
Relative β-cell
mass (%)
Fatty
Lean
Px
Saline (5)
Nicotinamide (6)
Phlorizin (7)
Sham
Remnant (6)
Whole (6)
Px
Saline (6)
Nicotinamide (6)
Sham
Remnant (6)
Whole (6)
8.67±1.53
8.27±1.39
11.47±2.02
34.76±4.53
113.90±13.55
30.33±2.58
25.66±2.34
23.40±2.64
31.54±4.55
24.01±4.17
17.50±3.13
34.38±7.43
120.18±20.17
235.74±26.21
86.93±8.09
71.44±6.99
66.72±6.32
106.41±6.39
4.56±0.61
5.84±0.80
3.69±0.54
8.85±0.23
38.32±3.86
3.36±0.37
2.98±0.44
3.72±0.53
14.46±1.34
1.24±0.13
1.24±0.18
1.08±0.14
3.00±0.17
7.21±0.17
0.96±0.10
0.83±0.12
1.08±0.14
2.35±0.17
2.21±0.68
1.73±0.59
3.57±0.73
3.91±0.47
3.08±0.54
9.38±0.96
9.59±1.57
7.11±1.45
4.59±0.63
Date are means±S.E. Nicotinamide and phlorizin doses were the same as for Table 1. The insulin content was calculated for each
rat as the product of insulin concentration and tissue weight. The β-cell mass was calculated for each rat as the product of relative
volume of β-cell mass(%), which was obtained by point-counting morphometrics and tissue weight. **p<0.01 vs. remnant equivalent
of Fatty sham, ##p<0.01 vs nicotinamide-treated Px Fatty.
Table 3. Differences in plasma glucose, IRI levels and anthropometric parameters between Wistar lean rats with homogeneous
(Fa/Fa) and heterogeneous (Fa/fa) genotype after partial pancreatectomy.
Fasting plasma
β-cell mass
(mg)
Rat Bs
(mmol/l)
IRI
(pmol/l)
LBM
(g)
Abdominal fat
(g)
Fat
(%)
Px Lean Nicotinamide
Fa/Fa (3)
Fa/fa (3)
Saline
Fa/Fa (3)
Fa/fa (3)
5.52±0.20
6.33±0.53
6.20±0.37
7.17±0.39
324.45±28.41
322.65±27.56
168.97±61.12
221.09±35.47
240.40±21.07
238.35±6.23
248.32±6.15
250.91±5.37
5.87±0.91
6.62±0.33
6.65±0.59
6.15±1.87
3.53±1.30
4.13±2.01
7.86±1.71
6.84±0.60
2.87±0.52
3.09±0.83
3.22±0.65
3.50±0.49
Data are means±S.E. LBM and Nicotinamide doses were the same as for Table 1.
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been suggested that hyperglycemia accelerates β-cell
mass growth by increasing the number of β-cells
undergoing mitosis (11, 12). In addition, a prolonged
hyperglycemia impairs, not only β-cell function, but
also proliferation, which is the result of the effect of
glucose, glucose toxicity (13). Phlorizin was used to
eliminate both of these effects of hyperglycemia on
β-cells. The results of the present study suggest that
the abnormality of the proliferative capacity in Wistar
fatty rats is unrelated to both the stimulative and
toxic effects of hyperglycemia. It can, therefore, be
concluded that the poor capacity for proliferation of
β-cells in this strain may be genetically determined.
The administration of nicotinamide, which is known
to induce the outgrowth of β-cells from undifferentiated
epithelial cells in human (14) and to increase β-cell
mass largely due to β-cell replication (15), induced
an increase in the size, but not the significant growth
of β-cell mass in the Px Wistar fatty rats. This is
reflected by the slight reduction of hyperglycemia
after surgery in the Px Wistar fatty rats treated with
nicotinamide, which was quite different from the results
obtained in the nicotinamide-treated Px OLETF rats.
The degree of obesity is far greater in the Wistar
fatty rats than the OLETF rats, which might result
in greater resistance to, and demand for insulin in
the former than the latter. This might in turn lead
to more extensive β-cell death and reduction of β-cell
mass exceeding the proliferation of β-cells induced
by nicotinamide in the Wistar fatty rats. Recently, we
(16, 17) and others (7, 18) discovered the substitution
at codon 269 of the leptin receptor cDNA in Zucker
fatty and Wistar fatty rats, which is thought to be a
cause of their hyperphagia and obesity (19). These
phenotypes are seen in rats with homogenous genotype,
fa/fa but not in the heterogeneous, Fa/? rats. It is now
possible to subgroup phenotypically identical lean
litter mates into those with a homogeneous Fa/Fa
and those with a heterogeneous, Fa/fa genotype by
genotype analysis. Thus facilitating a comparison of
any difference in physical characteristics and parameters
related to the carbohydrate metabolism. The results
showed no significant differences in these parameters
between both groups, suggesting that the defect of
leptin receptor per se is not related to the poor capacity
for proliferation of β-cell growth and, hence, leads
to a reduction in β-cell mass.
In summary, 70% pancreatectomy caused an immediate
and sustained hyperglycemia inWistar fatty rats, which
was associated with a reduction in β-cell mass and
a low plasma insulin concentration. This defect was
unaffected by restoration of normoglycemia when
phlorizin was used. These findings suggest that Wistar
fatty rats have a poor capacity for proliferation of
pancreatic β-cells, which causes the onset of overt
diabetes along with insulin resistance due to extreme
obesity.
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